Compare Ascendis Pharma A/S (ASND) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Inovio Pharmaceuticals Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: Ascendis Pharma A/S is far larger — about 181.2× Inovio Pharmaceuticals Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ASND | INO | |
|---|---|---|
Market Cap | $17.74B | $97.91M |
Sector | Health | Health |
52-Week High | $277.18 | $2.87 |
52-Week Low | $163.32 | $1.05 |
Enterprise Value | $18.11B | $68.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
